Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra and currently employs 394 full-time employees.  The firm is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The firm's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. The company provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The firm's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.

Kopran Dividends

524280.BO dividend metrics

Dividend per share

524280.BO dividend history